Sudocetaxel Zendusortide
- Generic Name
- Sudocetaxel Zendusortide
Sudocetaxel Zendusortide Shows Promise in Advanced Ovarian Cancer Phase 1b Trial
• Theratechnologies' sudocetaxel zendusortide demonstrates favorable tolerability and efficacy signals in heavily pre-treated ovarian cancer patients in a Phase 1b trial.
• No dose-limiting toxicities were observed in patients receiving weekly doses of sudocetaxel zendusortide, indicating a manageable safety profile.
• Preliminary efficacy data showed significant tumor shrinkage and complete resolution of a liver lesion in some patients at a 2.5-mg/kg/week dose.
• The Medical Review Committee recommends further evaluation and exploration of higher doses based on the encouraging tolerability and efficacy data.
Peptide-Drug Conjugates (PDCs) Emerge as Promising Targeted Cancer Therapies
• Peptide-drug conjugates (PDCs) are emerging as a novel class of cancer therapeutics, offering potential advantages over antibody-drug conjugates (ADCs) due to their smaller size and rapid internalization.
• PDCs targeting SORT1, a transmembrane glycoprotein highly expressed in various solid tumors, demonstrate enhanced drug delivery and reduced off-target toxicity in preclinical studies.
• Theratechnologies' SORT1+ Technology platform is advancing PDCs, with early clinical data showing durable disease stabilization and a unique mechanism of action in advanced solid tumors.
• The versatility of PDCs allows for conjugation with diverse payloads, including radioisotopes, opening new avenues for targeted cancer treatment and potential development partnerships.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath